LCN2 and Hyperglycemia: Taken together, these results suggest that the TonEBP may transcriptionally regulate systemic and neuroinflammation via the direct binding to position − 2827 of the LCN2 promoter region under diabetic conditions of low-grade inflammation and hyperglycemia.